Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 11

1.

Structure-function relationship of Vpr: biological implications.

Morellet N, Roques BP, Bouaziz S.

Curr HIV Res. 2009 Mar;7(2):184-210. Review.

PMID:
19275588
2.

Analysis of the potential for HIV-1 Vpr as an anti-cancer agent.

Muthumani K, Lambert VM, Sardesai NY, Kim JJ, Heller R, Weiner DB, Ugen KE.

Curr HIV Res. 2009 Mar;7(2):144-52. Review.

PMID:
19275583
3.

HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis.

Muthumani K, Choo AY, Hwang DS, Ugen KE, Weiner DB.

Curr Drug Deliv. 2004 Oct;1(4):335-44. Review.

PMID:
16305395
4.

HIV-1 viral protein R (Vpr) & host cellular responses.

Zhao RY, Bukrinsky M, Elder RT.

Indian J Med Res. 2005 Apr;121(4):270-86. Review.

PMID:
15817944
5.

Viral infections and cell cycle G2/M regulation.

Zhao RY, Elder RT.

Cell Res. 2005 Mar;15(3):143-9. Review.

6.

The Vpr protein from HIV-1: distinct roles along the viral life cycle.

Le Rouzic E, Benichou S.

Retrovirology. 2005 Feb 22;2:11. Review.

7.

HIV-1 Vpr and anti-inflammatory activity.

Muthumani K, Desai BM, Hwang DS, Choo AY, Laddy DJ, Thieu KP, Rao RG, Weiner DB.

DNA Cell Biol. 2004 Apr;23(4):239-47. Review.

PMID:
15142381
9.
10.

HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator.

Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ.

Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5281-6.

11.

HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B.

Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB.

Nat Med. 1997 Oct;3(10):1117-23.

PMID:
9334723

Supplemental Content

Support Center